JPWO2024034591A5 - - Google Patents
Info
- Publication number
- JPWO2024034591A5 JPWO2024034591A5 JP2024540479A JP2024540479A JPWO2024034591A5 JP WO2024034591 A5 JPWO2024034591 A5 JP WO2024034591A5 JP 2024540479 A JP2024540479 A JP 2024540479A JP 2024540479 A JP2024540479 A JP 2024540479A JP WO2024034591 A5 JPWO2024034591 A5 JP WO2024034591A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- group
- alkylene
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022126817 | 2022-08-09 | ||
| PCT/JP2023/028860 WO2024034591A1 (ja) | 2022-08-09 | 2023-08-08 | Ｋｒａｓタンパクを阻害及び／又は分解誘導するための複素環化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2024034591A1 JPWO2024034591A1 (https=) | 2024-02-15 |
| JPWO2024034591A5 true JPWO2024034591A5 (https=) | 2026-02-18 |
Family
ID=89851832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540479A Pending JPWO2024034591A1 (https=) | 2022-08-09 | 2023-08-08 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250388569A1 (https=) |
| EP (1) | EP4570794A1 (https=) |
| JP (1) | JPWO2024034591A1 (https=) |
| CN (1) | CN119768398A (https=) |
| TW (1) | TW202412790A (https=) |
| WO (1) | WO2024034591A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025052649A1 (ja) * | 2023-09-08 | 2025-03-13 | アステラス製薬株式会社 | 単一の軸不斉化合物の選択的製造法 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202545934A (zh) * | 2024-02-05 | 2025-12-01 | 日商安斯泰來製藥股份有限公司 | 包含具有突變ｋｒａｓ蛋白分解誘導作用之雜環化合物的抗體藥物複合體 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| CA3102996A1 (en) | 2018-07-20 | 2020-01-23 | Dana-Farber Cancer Institute, Inc. | Degraders that target proteins via keap1 |
| WO2020206608A1 (en) | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Methods and compositions for targeted protein degradation |
| TW202124374A (zh) | 2019-09-13 | 2021-07-01 | 美商拜歐斯瑞克斯公司 | Ras蛋白降解劑、其醫藥組合物及其治療應用 |
| US20220370416A1 (en) | 2020-04-06 | 2022-11-24 | Arvinas Operations, Inc. | Compounds and methods for targeted degradation of kras |
| WO2022002102A1 (en) | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
| CA3195457A1 (en) | 2020-10-14 | 2022-04-21 | Weiwen Ying | Methods and compositions for targeted protein degradation |
| KR20230088763A (ko) | 2020-10-14 | 2023-06-20 | 라녹 테라퓨틱스 (항저우) 컴퍼니, 리미티드 | 표적 단백질 분해를 위한 방법 및 조성물 |
| WO2022105855A1 (en) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| WO2022132200A1 (en) | 2020-12-15 | 2022-06-23 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| WO2022148421A1 (en) | 2021-01-08 | 2022-07-14 | Beigene, Ltd. | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| US20240140957A1 (en) | 2021-01-08 | 2024-05-02 | Beigene Switzerland Gmbh | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| KR20230145361A (ko) | 2021-02-15 | 2023-10-17 | 아스텔라스세이야쿠 가부시키가이샤 | G12d 변이 kras 단백의 분해를 유도하기 위한 퀴나졸린화합물 |
| WO2022228576A1 (zh) | 2021-04-30 | 2022-11-03 | 上海医药集团股份有限公司 | 一种靶向蛋白调节剂的化合物及其应用 |
| CN117460737A (zh) | 2021-07-05 | 2024-01-26 | 四川科伦博泰生物医药股份有限公司 | 杂芳环化合物、其制备方法及用途 |
| CN115785199A (zh) | 2021-09-10 | 2023-03-14 | 润佳（苏州）医药科技有限公司 | 一种双官能化合物及其用途 |
| WO2023077441A1 (en) | 2021-11-05 | 2023-05-11 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
-
2023
- 2023-08-08 TW TW112129767A patent/TW202412790A/zh unknown
- 2023-08-08 EP EP23852553.9A patent/EP4570794A1/en active Pending
- 2023-08-08 CN CN202380054760.8A patent/CN119768398A/zh active Pending
- 2023-08-08 US US18/880,332 patent/US20250388569A1/en active Pending
- 2023-08-08 WO PCT/JP2023/028860 patent/WO2024034591A1/ja not_active Ceased
- 2023-08-08 JP JP2024540479A patent/JPWO2024034591A1/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2024034591A5 (https=) | ||
| RU2353616C2 (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| SE8701605D0 (sv) | Novel medicinal compounds | |
| JP2006500370A5 (https=) | ||
| SE7701045L (sv) | Prostansyraderivat | |
| NO167920C (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive tricykliske 1,4-azepinderivater | |
| CA2164303A1 (en) | Aromatic Acetylcholinesterase Inhibitors | |
| ATE2519T1 (de) | N-phenoxyalkylpiperidin-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel. | |
| TW249224B (https=) | ||
| FI830380A0 (fi) | Pyridylfoereningar | |
| DE69432542D1 (de) | Tetraderivate, ihre Herstellung und Verwendung | |
| DE59409248D1 (de) | Verwendung von Phenalkylaminen zur Herstellung von cholesterinsenkenden Arzneimitteln | |
| DE69320895D1 (de) | Antibiotische Carbapenemverbindungen | |
| PT74199B (de) | Neue trisubstituierte pyrimido<5,4-d>pyrimidine ihre herstel- lung und ihre verwendung als arzneimittel | |
| JPS5283396A (en) | Novel compound physiologically acceptable salts thereof process for preparing same and medical composition containing same | |
| AR044343A1 (es) | Derivados de diarilmetilidenopiperidina, preparaciones de los mismos y usos de los mismos | |
| ATE170860T1 (de) | Antibiotische carbapenemverbindungen | |
| NO914567L (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridylderivater | |
| SE8005560L (sv) | Nya, hologenerade 15-hydroxi-e-homoeburnanderivat jemte sett for deras framstellning | |
| SE8003479L (sv) | Geminala dihalogenderivat av kondenserade pyrimidin-4-on foreningar, sett for deras framstellning och farmaceutiska beredningar innehallande dem | |
| RU2025134685A (ru) | ИНГИБИТОРЫ GSK3α И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| RU2004125289A (ru) | Способ получения производных морфолина и их промежуточных соединений | |
| SU741793A3 (ru) | Способ получени эргопептидалкалоидов или их солей | |
| AR044345A1 (es) | Derivados de diarilmetilidenpiperidina preparaciones de los mismos y usos de los mismos | |
| Valle | Aplicações de reações de cicloadição [2+ 2] envolvendo enecarbamatos endocíclicos de cinco membros e cetenos |